What Is Industrial Biotechnology? From the First Product to the First Plant

Industrial biotechnology uses living systems to make products that industries already know how to buy. The clearest explanation starts with the output, its scale and the reason a customer needs it, and brings in the biology as the production method. This guide follows that order from the first product a buyer can test, through scale-up, to the first plant story an investor checks.

Leah Bessa, CSO and co-founder of De Novo Dairy, a start-up that makes dairy proteins with precision fermentation, described the call that chose her company’s product in an interview published in January 2023. “We talked with a dairy company in Spain about a protein we had often encountered. The concentration of this protein is higher in dairy, so you tend to overlook it. They were talking about many of the challenges they have with this protein. Our technology could solve that very easily and at a reduced cost to what they're paying in the market.” She went on to the decision. “It was a very casual conversation, and when we ended the call, we all agreed that's our protein!” The buyer named the product and the price it already paid. The production method, engineered microbes making one specific protein, came second, as the reason De Novo Dairy could supply that protein for less. It is one founder’s recollection of one conversation, and it shows the order in which the field becomes legible to the people who buy from it.

The same order holds at commercial scale. In 2025 a new plant in Eddyville, Iowa began producing QIRA, a bio-based form of 1,4-butanediol (BDO). Qore, a joint venture between Cargill and HELM, announced the facility in 2021 as a $300 million build, with a design capacity reported at 66,000 metric tonnes a year. BDO is an industrial chemical used across materials including fibres, plastics and other downstream products. The announcement names the product, the scale and the industrial use, and gives the renewable attribute and customer demand as the reasons for the plant. The fermentation process, developed by Geno, sits underneath those claims as the method that makes the product possible.

Industrial biotechnology is a production system

Most people hear biotechnology and think first of medicines. Industrial biotechnology applies living organisms, cells and enzymes to production. The outputs include chemicals, materials, fuels, food and feed ingredients, agricultural inputs and other industrial goods.

Biomanufacturing is the operational part of that field. It asks whether the product can be made repeatedly, at volume, to specification and at a cost the market will accept. For a commercial reader, that is enough. Biology is the production method, the product is what the customer specifies and pays for, and biomanufacturing is how the company proves it can supply that product reliably.

The range of outputs explains why the word platform often creates confusion. A procurement manager at a chemicals company, a food formulator and a feed buyer are all dealing with industrial biotech, and they buy different things under different qualification rules. Each needs the company to name its output in the language of their own market.

Buyers start from the product they already use

Industrial biotech usually enters an existing supply chain. The customer already has a supplier, a specification, a price and a qualification process, so the new product has to fit a system that already works before its environmental or strategic advantage becomes valuable. The production method matters when it explains a difference the buyer values, such as price stability, performance, supply security, lower footprint or independence from a volatile feedstock.

Switching has a cost of its own. Qualification trials, supply contracts, compatibility with equipment, regulatory work and procurement approval all sit between interest and adoption, and being biological gives the buyer no automatic reason to accept those costs. The position has to say which part of the incumbent case changes and why the advantage is large enough to justify the switch. Our piece on technology vs product sets out the general order between the two stories.

Regulatory status belongs in the same comparison. The OECD has compared the innovation and regulatory environments for biotechnology and biosolutions in the EU and the US, and a product's status can differ from one market to the other. Say where the product is cleared, where approval is pending and where it has yet to enter the process.

1. 01ProcurementProduct, specification, price and supply.
2. 02Technical evaluatorOrganism, feedstock, titre, yield and purification.
3. 03InvestorAll of the above, plus scale-up risk, manufacturing strategy, market access and capital intensity.

Each reader needs a different depth of biology. Organise the layers for each one.

The first product has to be testable

A platform company may be able to produce many outputs. A buyer needs one they can test. The first product should have a defined buyer and application, measurable performance criteria, plausible economics, a regulatory path where one applies and a route to supply. A 2026 paper on minimum viable products in precision fermentation treats the first viable product as a milestone between research and market. In commercial terms it is the first output that meets a real buyer's specification at a volume they can meaningfully test.

Colipi, a Hamburg spin-off that uses fermentation to replace palm oil, cocoa butter and shea butter, chose its first market on those terms. Philipp Arbter, its co-founder, explained the choice in a September 2023 interview. “The primary focus for the next few years will be on the cosmetic industry because it has the lowest regulatory barriers and the greatest potential for the oil we produce to enter the market.” That is one founder’s plan at one moment. It picks a market where a buyer can test the product soon, with the wider platform to follow.

Fermentation is one route among several

Fermentation is the production route most people meet first. Microorganisms such as bacteria, yeast or fungi convert a feedstock into a target output inside a controlled vessel.

In biomass fermentation the organism itself becomes the product, as with some protein ingredients. In precision fermentation an engineered organism produces a specific molecule that is later separated and purified. Gas fermentation uses gases such as methane, carbon dioxide or hydrogen as feedstock in place of sugar. Industrial biotechnology also includes enzymatic processing, cell culture and systems that use plants or algae as production hosts. The production route explains why the output can be made, and the buyer should not have to translate the process into the thing they need to purchase.

That rule has a limit. Sometimes the route is part of what the customer buys. Christoph Pitter, co-founder of ProteinDistillery, explained in a November 2023 interview why his company left precision fermentation. “Over time, we realised precision fermentation was costly and difficult, especially in Germany, where consumers want something natural to connect with. It was also hard to sell the story to investors.” The company moved to natural proteins from yeast. That is one company’s account of one market, and in it the production method shaped both what consumers would accept and what investors would back. Where consumers or investors judge the route itself, the explanation has to carry it earlier, and the product still comes first.

Scale changes the evidence

A laboratory result shows that a pathway can produce a target molecule. Manufacturing has to show repeatability, quality, yield and economics at useful volume.

That introduces new questions about feedstock, contamination control, downstream separation, equipment, energy, utilities, quality systems and capacity. Organisms can behave differently in larger vessels because mixing, oxygen transfer and heat removal change. Downstream processing that looked minor at bench scale can become a major cost at industrial scale.

Investors put the question in the same terms. Anthony Chow, co-founder of Agronomics, which invests in cellular agriculture and precision fermentation, told Brighter Future in a June 2024 interview that the open question for his fund is “whether this can be done at an industrial scale and at a price point that is competitive with, if not cheaper than conventional agriculture.” He added what a retailer had told him. “I spoke with Sainsbury's, one of the largest UK retailers, and I was told that there are very few examples, where a premium-priced product has managed to take meaningful market share despite a perfectly functional cheaper alternative being available.” These are one investor’s views about food, and the retailer’s remark reaches us second-hand through him. They still describe the test that scale has to pass, a price the buyer can accept beside an alternative that already works.

The evidence therefore has to move from the best run to an operating range. A buyer and investor both need to know what the process can sustain, which variables move and what happens when a batch performs below target. This is why our separate guide on biomanufacturing scale-up focuses on the distribution of performance as well as the headline result. Show the spread of results across runs, and show the failed runs with what the team learned from each. That protects the company later. A plant that performs inside the range it promised has met its case. A plant that falls short of the best run it implied has a problem, even when the two produce the same output.

Label maturity and impact

Industrial biotech decks often place scientifically possible outputs beside pilot-produced and commercially available products as though they share one pipeline state. A buyer reads that blending as uncertainty about supply. Label each product by stage. A research output, a qualified sample, a pilot volume and a commercially available input each support different claims.

Environmental claims need the same discipline. Bio-based describes an origin or production route, and lower impact has to be shown by a comparison. The energy mix, feedstock, life-cycle boundary and incumbent all determine the result. The rule applies to our own client. Unibio uses gas fermentation to make protein for animal feed. Its chief executive told us that its demonstration facility in Denmark runs on biogas and that other sites will use natural gas from the grid, an exchange we cover in how to explain a technical product without oversimplifying it. A footprint claim for its protein therefore has to name the plant that supplies it. Brighter Future will not use the word bio-based as a substitute for an evidenced environmental claim.

BDO has an earlier public record that shows maturity labelled well. Genomatica developed a process it called GENO BDO to make butanediol by fermentation. In 2016 Novamont, which licensed that process for its Mater-Biotech plant in Italy, opened what it described as the world's first commercial plant for bio-production of a major intermediate chemical. In 2017 Genomatica announced that it had delivered on plant performance guarantees for that plant. The product was a named chemical with an existing market. The plant was a named site run by a named operator. The evidence that followed was a performance guarantee, which a plant owner, a lender and a customer can all use.

Tell the first plant story as claims an investor can check

A first commercial plant ties the biology to feedstock, fermentation assets, downstream processing, utilities, commissioning and offtake. Process engineers design each of those. The communication job is to state where each one stands, in terms a lender, an investor and a buyer can check. Our guides to what FOAK means in climate tech and moving from FOAK to NOAK cover the general first-of-a-kind questions of risk, offtake and financing.

Founders often describe a feedstock as waste, renewable or abundant. The case still has to state the delivered cost, the contracts behind it, the quality variation the process tolerates and the volume available at the site. Lenders price secured supply and treat a theoretical resource base as a hypothesis.

Titre, rate and yield, often shortened to TRY, connect the biology to the price, and researchers use them to evaluate production costs in microbial biotechnology. Titre is how much product each litre of broth holds. Rate is how fast a vessel makes it. Yield is how much product each unit of feedstock becomes. If the process improves one of them, say which one, by how much against which baseline, and what that does to cost in use for the customer. Each number has a pilot value, a first-plant design value and a later-plant target, and the three should never share a column. Label which figures are measured, which are vendor quotes, which are contracted and which are model assumptions.

Put the contamination record at the largest scale run so far in the deck, and the batch failure rate in the financial model. A model that assumes every batch succeeds tells a diligence team that nobody has run one yet. Downstream evidence belongs beside fermentation evidence, covering the recovery yield achieved at scale, the purity reached and the steps that have run on production-type equipment. A strong titre with an untested purification route is half a process.

The ramp to nameplate capacity, the full output the plant was designed for, usually takes longer than the first model assumed. State the ramp profile, the working capital it consumes and who carries the cost of a slow start. Biotech founders often have deep process knowledge and less experience delivering large projects. Explain how the team gains the capability to engineer, build, commission and operate the plant, whether through hires, an engineering partner or an operator.

An offtake agreement is a buyer's commitment to purchase the plant's output. In biomanufacturing it can also define the product specification, the qualification plan and the volume ramp the plant is built around. A non-binding letter of interest and a long-term purchase agreement sit at opposite ends of the range, and investors read the difference. Use the exact commercial status and tie the offtake terms to the ramp. The European Commission's 2026 bioeconomy measures connect new biobased manufacturing capacity with demand commitments and offtake. The wider mechanics are covered in what offtake means for FOAK climate tech.

Many companies rent fermentation capacity from a contract development and manufacturing organisation (CDMO) before they build their own plant. Contract capacity needs less capital and reaches customers sooner, with scheduling risk and shared margin. An owned plant gives control and long-term margin at the cost of capital and a longer path to first product. Liberation Labs, a US company, broke ground on its first purpose-built precision fermentation biomanufacturing facility in Richmond, Indiana, and in 2025 it announced a manufacturing partnership with Vivici, a precision fermentation dairy protein company. For Vivici, the partnership is a route to volume without owning a plant. For the facility, a named product partner is evidence of demand for its capacity. If you plan to start in contract capacity and move to an owned plant, name the trigger for the switch, whether a volume, a margin threshold or a customer commitment.

Show the scale gates and what the next raise buys

Investors find it easier to fund risk reduction they can see. Define the gates your next rounds will pass through and say which evidence closes each one. The gates vary by company. A typical sequence looks like this.

1. Technical performance at the current scale.
2. Repeatability and product quality across runs.
3. Customer qualification in a named application.
4. Demonstration economics against a costed model.
5. Commercial plant readiness, including site, engineering and feedstock.
6. Repeat deployment, where plant two costs less than plant one.

Then say what the next round creates and tie each tranche to a gate. A round that buys time without buying evidence leaves the next round facing the same questions at a higher valuation. A round that closes a named gate gives the next investor a smaller and better-defined risk to price. Draft the gates on one page, with the evidence, capital and expected date for each, and use that page as the spine of the deck and the data room. The first plant should also show what plant two can standardise. Some costs are one-off learning and others will repeat. Separating them makes a cost-down curve believable.

Policy belongs in the why-now section

The European Commission has continued work on biotechnology and biomanufacturing, including a 2026 consultation that asked how Europe can strengthen the business case and create demand in lead markets. The Circular Bio-based Europe Joint Undertaking, the EU's public-private funding partnership for bio-based industries, reported 272 proposals requesting €1.65 billion in funding in its 2026 call. That figure shows the scale of activity, and public funding and commercial adoption remain separate tests. For companies, policy explains why the moment has arrived. Buyers still purchase one product at a time.

Explain the field like an industry

A useful description of an industrial biotech company covers a short run of practical facts, written as prose. Name the product, the incumbent it replaces or complements, the buyer and application, the production route, the evidence at current scale, the manufacturing plan, the regulatory position where one applies and the supply available today. Then explain the biology at the depth the reader needs, which for procurement may be very little and for an investor reaches through scale-up and capital.

Brighter Future will not open a buyer story with the platform if the reader still cannot name the product. Industrial biotechnology becomes easier to understand when its stories read like the industries it is entering.

Most companies in the field need four pieces of material drawn from the same facts, each cut for a different reader. A buyer brief covers product, application, proof and supply. A technical pack covers mechanism, specification and validation data. An investor deck covers market shift, first product, platform, economics and scale. A plant case covers project, risk, offtake, capital and repeatability. Keep the numbers identical across all four. A yield figure that differs between the deck and the technical pack will be found in diligence, and it will cost more time than fixing it would have taken.

When the plant story is ready to meet investors, our biotech positioning and investor narrative work builds the deck and the project case around it.

Sources and further reading

• Leah Bessa, De Novo Dairy, founder interview, 2023
• Christoph Pitter, ProteinDistillery, founder interview, 2023
• Anthony Chow, Agronomics, investor interview, 2024
• Industrial biotechnology and biomanufacturing consultation, European Commission, 2026
• 2026 call attracts 272 proposals, Circular Bio-based Europe Joint Undertaking
• Cargill and HELM partner on renewable BDO facility
• QIRA production and 66,000 tonne annual capacity, Iowa Corn, 2025
• Philipp Arbter, Colipi, founder interview, 2023
• Minimum viable products in precision fermentation, Current Opinion in Biotechnology, 2026
• OECD comparison of EU and US biotechnology environments
• How to Explain a Technical Product Without Oversimplifying It
• Novamont opens world's first commercial plant for bio-production of a major intermediate chemical, GlobeNewswire, 2016
• Genomatica delivers on plant performance guarantees, GlobeNewswire, 2017
• TRYing to evaluate production costs in microbial biotechnology, Trends in Biotechnology, 2024
• Commission steps up action on EU bioeconomy, European Commission, 2026
• Liberation Labs breaks ground on first purpose-built precision fermentation biomanufacturing facility, Yahoo Finance
• Liberation Labs announces manufacturing partnership with Vivici, GlobeNewswire, 2025